BRAINSTORM CELL THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Financial Statements and Supplementary Data
AS OF DECEMBER 31, 2023
U.S. DOLLARS IN THOUSANDS
AS OF DECEMBER 31, 2023
U.S. DOLLARS IN THOUSANDS
(Except share data and exercise prices)
INDEX
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 1197) | 84 |
| Consolidated Balance Sheets | 86 |
| Consolidated Statements of Comprehensive Loss | 87 |
| Statements of Changes in Stockholders’ Equity | 88 |
| Consolidated Statements of Cash Flows | 90 |
| Notes to Consolidated Financial Statements | 92 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.